Jose Prieto, DO
Internal Medicine · Winter Haven, FLNPI 1144509480
Payments from drug & device makers
Across 471 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$853
- GSK$819
- Amgen$755
- Boehringer Ingelheim$690
- Bayer$639
- AstraZeneca$599
- plus $4K from 29 others
What the payments were for
- Food & beverage$8,65299%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 50 | $853 |
| GSK | 48 | $819 |
| Amgen | 47 | $755 |
| Boehringer Ingelheim | 36 | $690 |
| Bayer | 31 | $639 |
| AstraZeneca | 33 | $599 |
| Novo Nordisk | 28 | $532 |
| Merck | 24 | $463 |
| AbbVie(2 entities) | 21 | $411 |
| Sanofi-aventis U.S. LLC | 21 | $392 |
| Lilly USA, LLC | 19 | $366 |
| Novartis | 16 | $324 |
| Johnson & Johnson | 17 | $310 |
| Abbott | 11 | $233 |
| Esperion Therapeutics, Inc. | 9 | $185 |
| Daiichi Sankyo Inc. | 8 | $151 |
| Astellas Pharma US Inc | 8 | $142 |
| Dexcom, Inc. | 7 | $133 |
| Exact Sciences | 5 | $112 |
| Kowa Pharmaceuticals America, Inc. | 6 | $95 |
| Mylan Specialty L.p. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Gilead | 3 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Global Blood Therapeutics, Inc. | 2 | $35 |
| Insmed, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Inogen, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$8,697 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 345 | $347,007 |
| JardianceEmpagliflozin | 219 | $240,543 |
| OzempicSemaglutide | 121 | $155,683 |
| XareltoRivaroxaban | 109 | $97,933 |
| EntrestoSacubitril/Valsartan | 65 | $78,947 |
| MyrbetriqMirabegron | 100 | $69,590 |
| ProliaDenosumab | 36 | $63,139 |
| TrulicityDulaglutide | 43 | $56,156 |
| FarxigaDapagliflozin Propanediol | 42 | $53,078 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $37,325 |
| MounjaroTirzepatide | 26 | $36,439 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $34,718 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 41 | $33,276 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $32,432 |
| Repatha SureclickEvolocumab | 21 | $27,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $853 | $347,007345 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $690 | $264,464247 claims |
| Novo NordiskOzempic | $532 | $155,683121 claims |
| Johnson & JohnsonXarelto | $310 | $97,933109 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $599 | $94,570103 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $366 | $92,59569 claims |
| NovartisEntresto | $324 | $78,94765 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $819 | $73,519111 claims |
| Astellas Pharma US IncMyrbetriq | $142 | $69,590100 claims |
| AmgenProlia | $755 | $63,13936 claims |
| AbbVieLinzess, Namzaric, Synthroid | $411 | $43,718108 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $392 | $33,27641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Winter Haven
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.